American Family Children's Hospital
Douglas G. McNeel, MD, PhD close
Douglas G. McNeel, MD, PhD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Douglas G. McNeel, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. McNeel is a genitourinary medical oncologist with a clinical and research focus on prostate cancer immunology. Since 1997 he and his laboratory have studied vaccines for prostate cancer, specifically identifying antigens to target in vaccines, testing the ability of vaccines to eliminate prostate cancer cells and translating these studies to human clinical trials.


Medical Oncology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship University of Washington School of Medicine, Seattle, WA, WA, WA
Fred Hutchinson Cancer Research Center
Residency University of Washington School of Medicine, Seattle, WA, WA, WA
Internship University of Washington School of Medicine, Seattle, WA, WA, WA
Medical School University of Chicago, Pritzker School of Medicine, Chicago, IL, 1994


Best Doctors® in America 2015

Best Doctors® in America 2014

Best Doctors® in America 2013


Languages Spoken

English, French
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Zahm CD Colluru V McNeel DG . Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1Expression on CD8+ T Cells. Cancer Immunol Res. 2017 Jun 20;
[PubMed ID: 28634215]
Zahm CD Colluru VT McNeel DG . DNA vaccines for prostate cancer. Pharmacol Ther. 2017 Jun;174:27-42
[PubMed ID: 28185916]
Ehlerding EB England CG Majewski RL Valdovinos HF Jiang D Liu G McNeel DG Nickles RJ Cai W . ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. Mol Pharm. 2017 May 1;14(5):1782-1789
[PubMed ID: 28388076]
Olson BM Bradley ES Sawicki T Zhong W Ranheim EA Bloom JE Colluru VT Johnson LE Rekoske BT Eickhoff JC McNeel DG . Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). Prostate. 2017 May;77(7):812-821
[PubMed ID: 28181678]
England CG Ehlerding EB Hernandez R Rekoske BT Graves SA Sun H Liu G McNeel DG Barnhart TE Cai W . Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017 Jan;58(1):162-168
[PubMed ID: 27493273]
McNeel DG Bander NH Beer TM Drake CG Fong L Harrelson S Kantoff PW Madan RA Oh WK Peace DJ Petrylak DP Porterfield H Sartor O Shore ND Slovin SF Stein MN Vieweg J Gulley JL . The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016;4:92
[PubMed ID: 28031820]
Heninger E Krueger TE Thiede SM Sperger JM Byers BL Kircher MR Kosoff D Yang B Jarrard DF McNeel DG Lang JM . Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. 2016 Dec 20;7(51):84359-84374
[PubMed ID: 27769045]
Rekoske BT McNeel DG . Immunotherapy for prostate cancer: False promises or true hope? Cancer. 2016 Dec 1;122(23):3598-3607
[PubMed ID: 27649312]
Choueiri TK Fishman MN Escudier B McDermott DF Drake CG Kluger H Stadler WM Perez-Gracia JL McNeel DG Curti B Harrison MR Plimack ER Appleman L Fong L Albiges L Cohen L Young TC Chasalow SD Ross-Macdonald P Srivastava S Jure-Kunkel M Kurland JF Simon JS Sznol M . Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15;22(22):5461-5471
[PubMed ID: 27169994]
McNeel DG . TCR diversity - a universal cancer immunotherapy biomarker? J Immunother Cancer. 2016;4:69
[PubMed ID: 27879971]
Colluru VT McNeel DG . B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget. 2016 Oct 18;7(42):67901-67918
[PubMed ID: 27661128]
Ehlerding EB England CG McNeel DG Cai W . Molecular Imaging of Immunotherapy Targets in Cancer. J Nucl Med. 2016 Oct;57(10):1487-1492
[PubMed ID: 27469363]
Colluru VT Zahm CD McNeel DG . Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses. Oncoimmunology. 2016;5(10):e1223002
[PubMed ID: 27853647]
Bloom JE McNeel DG . SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget. 2016 Aug 9;7(32):50997-51011
[PubMed ID: 27276714]
Colluru VT Johnson LE Olson BM McNeel DG . Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2016 Apr;34(4):193-204
[PubMed ID: 24332642]
Rekoske BT Olson BM McNeel DG . Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016 Jun;5(6):e1165377
[PubMed ID: 27471641]
Rekoske BT Smith HA Olson BM Maricque BB McNeel DG . PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res. 2015 Aug;3(8):946-55
[PubMed ID: 26041735]
McNeel DG Chen YH Gulley JL Dwyer AJ Madan RA Carducci MA DiPaola RS . Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother. 2015;11(10):2469-74
[PubMed ID: 26111351]
McNeel DG Gardner TA Higano CS Kantoff PW Small EJ Wener MH Sims RB DeVries T Sheikh NA Dreicer R . A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014 Oct;2(10):988-99
[PubMed ID: 25189164]
McNeel DG Becker JT Eickhoff JC Johnson LE Bradley E Pohlkamp I Staab MJ Liu G Wilding G Olson BM . Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014 Jul 15;20(14):3692-704
[PubMed ID: 24850844]